Clinical Trials

CNS

Glioblastoma

NCT06210334 2024-02-20

HAI-TL

54 enrolled

Carcinoma, Hepatocellular

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Carcinoma, Hepatocellular

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06233981 2024-01-31

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Carcinoma, Hepatocellular

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Triple Negative Breast Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

39 enrolled

Colorectal Neoplasms

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

85 enrolled

Other solid neoplasm

Advanced HCC

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

36 enrolled

Stomach Neoplasms

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05533892 2023-12-19

CCGLC-007

Phase 1 Unknown

Carcinoma, Hepatocellular

NCT05578287 2023-12-07

DETECT

29 enrolled

Colorectal Neoplasms

NCT06154967 2023-12-04

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Phase NA Unknown

20 enrolled

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

41 enrolled

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

21 enrolled

Small Cell Lung Carcinoma

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

105 enrolled

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

43 enrolled

HER2-positive Gastric Cancer

NCT05840835 2023-08-08

IMMINENT-01

Other solid neoplasm

Advanced Solid Tumor

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Phase 1 Unknown

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05603065 2023-06-29

TINES

Phase 4 Unknown

32 enrolled

Esophageal Squamous Cell Carcinoma

NCT05823987 2023-06-27

OPTIONS-05

Advanced Biliary Tract Cancer

NCT05893056 2023-06-27

CASTLE-09

Gastric Cancer Metastatic to Liver

NCT05897268 2023-06-27

CASTLE-10

Carcinoma, Hepatocellular

NCT05751265 2023-06-22

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

132 enrolled

Advanced Squamous Non-Small-Cell Lung Cancer

NCT05681390 2023-06-09

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

Pancreatic Neoplasms

NCT05896059 2023-06-09

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

21 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05527808 2023-06-08

A Single-arm Exploratory Study of Neoadjuvant Therapy

Phase NA Unknown

28 enrolled

Adenocarcinoma of Lung

NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Phase 4 Unknown

42 enrolled

Breast Neoplasms

NCT05420584 2023-05-11

NECI

83 enrolled

Rectal Neoplasms

NCT04542369 2023-05-03

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

15 enrolled

Small Cell Lung Carcinoma

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

LymphoidOther solid neoplasm

309 enrolled

Solid Tumor

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

Carcinoma, Hepatocellular

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05811793 2023-04-13

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Phase NA Unknown

36 enrolled

CNS

Glioblastoma

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Triple Negative Breast Neoplasms

NCT05799443 2023-04-05

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

23 enrolled

Colorectal Neoplasms

NCT04663035 2023-03-22

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

120 enrolled

Carcinoma, Hepatocellular

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

80 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04985721 2023-03-15

IMPARP-HRD

Tumor-Agnostic

Neoplasms

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1 Unknown

Carcinoma, Hepatocellular

NCT05718167 2023-02-14

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Phase 3 Unknown

570 enrolled

Advanced Squamous Non-Small Cell Lung Carcinoma

NCT05325528 2023-02-01

Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases

Phase 2/3 Unknown

40 enrolled

Stomach Neoplasms

NCT05445648 2022-12-28

CBPTMI

65 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

20 enrolled

Head & Neck

Thyroid Neoplasms

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled